Sansheng pharmaceutical's revenue increased by 27.4% year on year in the first half of 2018

August 20, 2018 / Meitong news agency / -- China's leading biopharmaceutical company Sansheng Pharmaceutical (01530 HK) today announced its first half of 2018 results, which show that the company has a strong growth in the first half of 2018 and all businesses have been comprehensively promoted In the future, the company will continue to maintain the platform advantage integrating R & D, production and marketing, consolidate its leading position in China's biopharmaceutical industry, and solve unmet medical needs and benefit more patients by focusing on the development of innovative biopharmaceutical products Financial report data shows that in the first half of 2018, the company's total operating revenue was about 2.174 billion yuan, an increase of 27.4% over the same period last year; gross profit was about 1.747 billion yuan, an increase of 19.9% over the same period last year; normalized EBITDA was about 838 million yuan, an increase of 25.7% over the same period last year; normalized net profit was about 561 million yuan, an increase of 37.8% over the same period last year The growth of core products is strong in the first half of 2018 Four core products of the company, tebio, yisepu, yibio and saibor, continue to maintain the leading position in the Chinese market According to IMS data, as the only commercial recombinant human thrombopoietin product in the world, tebio's market share in the first half of 2018 increased to 63.2%; its market share in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis increased to 63.5%; its market share in the two recombinant human erythropoietin products, ibio and saibor 41.3% On May 25 of this year, the company and AstraZeneca's baidayang, as the first weekly antidiabetic drug in China, brought new treatment options for type 2 diabetes patients In 2018, the company continuously enriched its product portfolio In the field of Nephrology, there are two new products: one is the pruritus product TRK-820 ("remitch") with which the company has signed an exclusive license agreement with Toray Japan, and the other is calcium acetate, a hyperphosphatemic product for the treatment of patients with chronic kidney disease, purchased from a pharmaceutical company BMT in Beijing At the same time, in the field of Dermatology, fluticasone propionate cream for the treatment of a variety of skin diseases was launched in March this year Laiz (pediatric indication) for the treatment of children's moderate to severe specific dermatitis was approved by the State Drug Administration A number of businesses have been developing rapidly in the first half of the year, and a number of businesses have developed together: in terms of research and development, the company has completed the three phase trial of the etanercept prefilled syringe and clindamycin phosphate A acid gel (for local treatment of acne vulgaris); the second generation recombinant human erythropoietin product NuPIAO (SSS06) for anemia (SSS06) Several phase I clinical trials have been completed, and the approval documents of phase II and phase III clinical trials have been obtained; anti epidermal growth factor receptor antibody 602 for tumor treatment has completed the group work of phase I clinical trials, and it is planned to carry out phase III clinical trials in patients with colorectal cancer; Ted for children's immune thrombocytopenia Approval and initiation of trials of patients with liver dysfunction at risk of thrombocytopenia; anti VEGF antibody 601a for macular edema, myopic choroidal neovascularization (mcnv), and diabetic macular edema (DME) due to retinal vein occlusion (RVO) Three clinical trials were approved, and the patients who started the first phase clinical trial of senile macular degeneration (AMD) were enrolled in the group; the anti HER2 monoclonal antibody drug 302H, which was used to treat breast cancer, had recently submitted the new drug marketing license application to the State Drug Administration In addition, in April 2018, the company and refuge biotechnology, Inc ("refuge") launched a cooperative research on the development of programmed cell therapy As of June 30, 2018, the company has 32 products under research, covering five fields including oncology, autoimmune diseases and other diseases, Nephrology, metabolism and dermatology, 17 of which are national first-class new drugs Focusing on the development of high-quality innovative biopharmaceuticals and looking into the future, Sansheng pharmaceutical will make use of a platform integrating R & D, production and commercial promotion to build a global leading pharmaceutical company based in China The company will focus on the development of leading Biopharmaceutics, including nupiao, rd001, sss07, pegsiticase, 602, 601a, yisaipu's pre filled injection and other monoclonal antibody products, and fully integrate multiple R & D platforms to promote the development of Biopharmaceutics, so as to bring a variety of treatment options for patients With the company's about 38000 liter capacity of monoclonal antibody facilities, as well as mammalian cells, bacteria and small molecule production facilities, as well as more than 25 years of experience in the field of biomedical manufacturing, the company provides high-quality drugs with competitive cost and large-scale production capacity, and strives to build a profitable CMO business In addition, the company will continue to selectively seek opportunities for M & A and cooperation to enrich the existing product portfolio and products under research, solve the unmet clinical needs, and provide a wealth of urgently needed products for the majority of patients The cooperation with AstraZeneca, Lilly and Toray reflects the group's excellent professional ability in international development and operation, laying a good foundation for the company's future internationalization strategy At the same time, the company's existing products are being registered in new countries, and new products are registered in highly regulated markets through the approval of innovative or biological similar drugs, so as to further expand international business and benefit the vast number of patients around the world Dr Lou Jing, chairman of Sansheng pharmaceutical, said: "with the improvement of living standards and the aging population, people's demand for high-quality medical products is increasing Sansheng pharmaceutical has always been based on innovation and regards product quality as the first lifeline of the enterprise In the future, the company will continue to focus on the field of biopharmaceutical, providing innovative, affordable and global quality standard drugs to the public to meet the needs of more patients "